Aidoc secures FDA clearance for first AI triage system covering 14 acute conditions in CT
Aidoc’s CARE AI gets FDA clearance for 14-condition CT triage. Find out how it may reshape emergency imaging, hospital workflows, and clinical AI governance.
Is Zepto Life Technology redefining fungal diagnostics with cell-free DNA technology?
Zepto Life Technology’s FungiFlex Mold Panel enables fast, noninvasive fungal diagnostics from blood. Find out what this could mean for patient care.
Why ProRx’s needle-free TRT could reshape hormone therapy for med spas and DTC providers
ProRx Pharma launches oral testosterone for virtual care delivery. Find out what this means for telehealth TRT models and compounder-led hormone therapy.
BioStem acquires Neox and Clarix as BioTissue refocuses on eye care therapies
BioTissue exits surgical wound care to refocus on eye care innovation, selling Neox and Clarix lines to BioStem. Find out what this deal changes in MedTech.
Resolve M Therapeutics exits stealth with Johnson & Johnson Innovation support to pursue MS1-driven immune resolution
Resolve M exits stealth with a bold MS1-based approach to inflammation. Learn how its pro-resolution platform could reshape autoimmune drug development.
Can philanthropic capital succeed where pharma failed in Gram-negative antibiotic discovery?
Will Gr-ADI fix the broken antibiotic pipeline? Explore how Gates, Novo, and Wellcome aim to reboot AMR innovation with $60M in global grants.
Is this the end of EMFACE lookalikes? Inside BTL’s cross-border IP enforcement playbook
BTL’s EMFACE wins global IP battle against WonderFace. Find out how this reshapes the energy-based facial therapy market in 2026.
Can EpiSwitch PSE become more than a diagnostic tool in prostate disease management?
Doctors Studio’s ozone pilot shows promising 30-day shifts in prostate biomarkers tracked via EpiSwitch PSE. Could this reshape trial design? Find out.
Avacta Therapeutics (LSE: AVCT) advances FAP-targeting drug conjugate AVA6103 into Phase 1: What’s at stake?
Avacta Therapeutics (LSE: AVCT) has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration for AVA6103 (also known as FAP-Exd), its second clinical-stage asset developed using the company’s proprietary pre|CISION platform. The IND clearance enables the start of a Phase 1 trial evaluating the safety, tolerability, and dose parameters of […]
What the Trinity Tube reveals about the future of multifunctional devices in NICU care
Can a feeding tube that monitors vitals change neonatal care? See why Neotech is backing this multifunctional device startup.